Latest Research & Analysis

1-Sep-2021 - Natera Inc. – NTRA:  SEC Investigation Updates 01-Sep-2021 - Natera Inc. – NTRA: $118.43 Mkt Cap. $11.1 B  Removed from Watch List.  We’ve already written extensively on problems we found at Natera.  Now we received 10 more pages of records, dated Sep-2019 to Jan-...

1-Sep-2021 - Salesforce.com, Inc. – CRM:  SEC Investigation Updates 01-Sep-2021 - Salesforce.com Inc. – CRM   $265.27  Mkt Cap $245.6 Removed from Watch List.  We received one page of records, dated 21-May-2021, from an undisclosed SEC investigation of CRM. It only shows...

31-Aug-2021 - Company’s appearing in today’s research update -- Allogene Therapeutics, Inc. – ALLO  Brixmor Property Group, Inc. – BRX  Collegium Pharmaceutical, Inc. – COLL Gentex Corp. – GNTX  Novavax, Inc. – NVAX  Owens & Minor, Inc. – OMI SunPower...

31-Aug-2021 - Allogene Therapeutics, Inc. – ALLO:  SEC Investigation Update Probes Reporter® research provides data, commentary, and analysis on public company interactions with investors and with the SEC.   Our work is heavily reliant on company disclosures and our expertise in...

31-Aug-2021 - Brixmor Property Group, Inc. – BRX:    SEC Investigation Update Probes Reporter® research provides data, commentary, and analysis on public company interactions with investors and with the SEC.   Our work is heavily reliant on company disclosures and our...

31-Aug-2021 - Collegium Pharmaceutical, Inc. – COLL:  SEC Investigation Update Probes Reporter® research provides data, commentary, and analysis on public company interactions with investors and with the SEC.   Our work is heavily reliant on company disclosures and our expertise in...

31-Aug-2021 - Gentex Corp. – GNTX:  SEC Investigation Update Probes Reporter® research provides data, commentary, and analysis on public company interactions with investors and with the SEC.   Our work is heavily reliant on company disclosures and our expertise in using the Freedom...

31-Aug-2021 - Novavax, Inc. – NVAX  Probes Reporter® research provides data, commentary, and analysis on public company interactions with investors and with the SEC.   Our work is heavily reliant on company disclosures and our expertise in using the Freedom of Information Act. The...

Pages